Glucagon in Pediatric Metabolic Disorders: Pathophysiology and Therapeutic Perspectives
Over the past century of research, it has become increasingly evident that glucagon should no longer be regarded solely as a counter-regulatory hormone to insulin. Its role in the pathophysiology of metabolic disorders—including diabetes, obesity, and non-alcoholic fatty liver disease—appears to be...
| Published in: | Pediatric Reports |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-10-01
|
| Subjects: | |
| Online Access: | https://www.mdpi.com/2036-7503/17/5/104 |